Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Clinical Trials

At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Mathew Davids from the Dana-Farber Cancer Institute in Boston interviews Dr. Bill Wierda from the MD Anderson Cancer Center in Houston. They discuss the benefits of combined finite therapy to achieve U-MRD with a
Considering a clinical trial may seem like a daunting prospect, but sometimes it can be the smartest strategy. Here are some basic questions to help you make a good decision. 1. What is a clinical trial? The search for new and better treatments for chronic lymphocytic leukemia/small lymphocytic lymphoma
This abstract from the American Society of Hematology Annual Meeting and Exposition (ASH 2021) presented interim results of the Phase 3 randomized SEQUOIA study which evaluated the efficacy and safety of zanubrutinib versus BR in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients without the high-risk mutation,17p deletion
Treatments for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) are being developed to address refractory cases, in other words, those that no longer respond to current therapies. In this study presented at the American Society of Hematology Annual Meeting and Exhibition (ASH 2021), the results of early (phase